If GP73 is further developed and analyzed to determine whether it is able to distinguish patients with hepatitis and cirrhosis from patients with HCC, one should take into account that GP73 is also elevated in benign liver tumors. This evidence concerns the gene GOLM1 and hepatocellular carcinoma.